Boston Scientific announces FDA clearance of next-generation PCI guidance system
Click Here to Manage Email Alerts
Key takeaways:
- Boston Scientific announced the FDA cleared its next-generation IVUS and FFR guidance system.
- The system uses artificial intelligence to automate key steps during PCI.
Boston Scientific announced the FDA clearance of its next-generation IVUS and fractional flow reserve system designed improve guidance during PCI.
The guidance system (AVVIGO+ Multi-Modality Guidance System) uses an artificial intelligence software (Automated Lesion Assessment) to automate key procedural steps, provide precise vessel measurements and expedite the acquisition of IVUS images during PCI, the company stated in an email to Healio.
Image: Adobe Stock
During PCI, physicians are also guided by the system drawing a physiology graph, providing a roadmap of the diseased coronary artery, the company stated.
“We are pleased to introduce U.S. clinicians to the next-generation AVVIGO+ Multi-Modality Guidance System, which builds upon the AVVIGO Guidance System II and provides fast, intuitive and accurate vessel and lesion assessment capabilities for percutaneous coronary interventions,” Lance Bates, president of interventional cardiology therapies at Boston Scientific, said in the email. “Coming on the heels of the updated ACC guidelines recommending intracoronary imaging during PCIs, we believe this enhanced and automated tool will help physicians optimize these procedures to provide better outcomes for their patients with coronary artery disease.”
Collapse
Press Release
Click Here to Manage Email Alerts